Michael Severino - Articles and news items

AbbVie Logo

AbbVie announces initiation of pivotal Phase III study of Veliparib (ABT-888) in patients with advanced breast cancer

Industry news / 26 June 2014 / AbbVie

AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)…

Biogen Idec logo

Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis

Industry news / 16 June 2014 / Biogen Idec

Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process…

AbbVie Logo

AbbVie announces Michael Severino, M.D. to lead R&D organization and drive continued pipeline advancement

Industry news / 19 May 2014 / AbbVie

AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development and Chief Scientific Officer…

Amgen logo

Amgen announces top-line results of Phase 3 Aranesp® (darbepoetin alfa) RED-HF® trial

Industry news, News / 16 January 2013 / Amgen

Amgen announced top-line results of the Phase 3 Aranesp® RED-HF® Trial…

Amgen logo

Phase 3 Sensipar® / Mimpara® EVOLVE(TM) trial published in the New England Journal of Medicine

Industry news, News / 3 November 2012 / Amgen

Study results presented at American Society of Nephrology’s Kidney Week…

Amgen logo
Amgen logo

Amgen names Michael Severino, M.D., Senior VP, Global Development and Corporate Chief Medical Officer

Industry news, News / 14 February 2012 / Amgen

“Mike brings broad experience and immense expertise to his new role…”


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...